Home > Sickle Cell Disease > Dosing and Administration
Sickle Cell Disease Dosing and Administration

Dose-dependent Reductions in Liver Iron Concentration Demonstrated at 1 Year

EXJADE Delivers Dose-dependent Reductions in Liver Iron Concentration1
Change in Liver Iron Concentration

Data from a 1-year, open-label phase II trial, evaluating the safety and tolerability of EXJADE. Efficacy was measured by change in liver iron concentration (LIC) using biosusceptometry. Adjusted change (mean + SD) in LIC determined according to assigned treatment category for EXJADE.1

Titrate and monitor to reach chelation goals2

  • The recommended daily starting dose of EXJADE is 20 mg/kg body weight
  • Monitor serum ferritin monthly and assess trends with steady-state levels
  • Titrate EXJADE by steps of 5 mg/kg/day to 10 mg/kg/day every 3 to 6 months based on individual patient's response and therapeutic goals (maintenance or reduction of iron)
  • EXJADE is approved at doses up to 40 mg/kg/day for patients not adequately controlled with doses of 30 mg/kg (eg, serum ferritin levels persistently above 2,500 μg/l and not showing a decreasing trend over time)
  • Doses above 40 mg/kg are not recommended because there is only limited experience with doses above this level
  • Dose reductions, in steps of 5 to 10 mg/kg, should be considered in patients whose serum ferritin levels have reached the target (usually between 500 and 1000 μg/L) in order to maintain serum ferritin levels within the target range
Learn more about monitoring


Titrate from the recommended starting dose of 20 mg/kg/day based on individual patient′s response and therapeutic goals. Please check the Prescribing Information for your region for details.

Learn more


Help ensure your patients properly take their once-daily oral therapy.

Learn more